Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

Background: The benefit of dual antiplatelet therapy (DAPT) for reducing ischemic events is
greatest in the early period of acute coronary syndrome, and recent randomized controlled …

Aims Dual-antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is the
standard treatment for patients with acute coronary syndrome (ACS) undergoing …

The synergistic blockade of the key platelet signaling pathways of cyclooxygenase-1
blockade and P2Y12 signaling by combining aspirin plus a potent P2Y12 inhibitor …

Stable coronary artery disease (CAD) has recently been replaced by a new entity described
as chronic coronary syndrome (CCS). This new entity has been developed based on a …

BACKGROUND: Short-term (≤ 6 months) dual antiplatelet therapy (DAPT) and DAPT de-
escalation become attractive for patients with acute coronary syndrome. METHODS: A …

BACKGROUND: Dual antiplatelet therapy with a potent P2Y12 inhibitor coupled with aspirin
for 1 year is the recommended treatment for patients with acute coronary syndrome (ACS) …

The key role played by platelets in the atherosclerosis physiopathology, especially in the
acute setting, is ascertained: they are the main actors during thrombus formation and, thus …

Dual antiplatelet therapy (DAPT) is the standard approach to prevent thrombotic events in
patients undergoing percutaneous coronary intervention and presenting with chronic or …